Dose-adapted post-transplant cyclophosphamide for HLA-haploidentical transplantation in Fanconi anemia.
Bone Marrow Transplant
; 52(4): 570-573, 2017 Apr.
Article
en En
| MEDLINE
| ID: mdl-28067886
ABSTRACT
We developed a haploidentical transplantation protocol with post-transplant cyclophosphamide (CY) for in vivo T-cell depletion (TCD) using a novel adapted-dosing schedule (25 mg/kg on days +3 and +4) for Fanconi anemia (FA). With median follow-up of 3 years (range, 37 days to 6.2 years), all six patients engrafted. Two patients with multiple pre-transplant comorbidities died, one from sepsis and one from sepsis with associated chronic GVHD. Four patients without preexisting comorbidities and early transplant referrals are alive with 100% donor chimerism and excellent performance status. We conclude that adjusted-dosing post-transplant CY is effective in in vivo TCD to promote full donor engraftment in patients with FA.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Depleción Linfocítica
/
Ciclofosfamida
/
Anemia de Fanconi
/
Trasplante Haploidéntico
Límite:
Child
/
Child, preschool
/
Female
/
Humans
/
Male
Idioma:
En
Año:
2017
Tipo del documento:
Article